#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Glomerulonephritis membranoproliferative Choroid melanoma Familial hypertriglyceridaemia Obliterative bronchiolitis Glomerulonephritis rapidly progressive Homocystinuria Hereditary ataxia Encephalitis autoimmune Mucopolysaccharidosis III Gestational trophoblastic tumour Hodgkin's disease refractory Enteritis Dementia Wolfram syndrome Progressive supranuclear palsy More trials…

    Learn about Rare Diseases

    Alagille syndrome Systemic sclerosis pulmonary – Diagnostics Myxofibrosarcoma – Basic Information Piriformis syndrome – Treatment Anaplastic thyroid cancer Haemophilia A without inhibitors – Diagnostics Short-bowel syndrome – Trials in Disease Fabry’s disease – Treatment Mantle cell lymphoma stage III – Trials in Disease Netherton’s syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Rifapentine Aldesleukin Bi-1808 Lifileucel Lenzumestrocel Guselkumab Sparsentan Ziclumeran Methylprednisolone Silibinin FOSFOMYCIN CALCIUM Magnesium Hydroxide ANTIMETABOLITES Desloratadine RIMIDUCID Abelacimab GSKVX000000044501 Sultiame Tiotropium Bromide Monohydrate Lepidoglyphus Destructor More therapies…

    Learn about Your Condition

    Cholangiocarcinoma Arthroscopy Respiratory distress Right ventricular dysfunction Glomerulonephritis Hypothyroidism Colorectal cancer stage II Apathy Genital herpes Pre-eclampsia Transplant rejection Colon cancer stage III Oropharyngeal cancer recurrent Testis cancer Mucopolysaccharidosis III More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Medical University Of Gdansk

Medical University Of Gdansk

Ul. Debinki 7, Gdansk, 80-211, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • A study of EP0031 and drug combination for patients with advanced cancers having changes in the RET gene

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Medullary thyroid cancer
    • Neoplasm malignant
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Ep0031
    • Carboplatin
    • Cisplatin
    France Germany Italy Poland Spain

  • Study of drug combinations including cisplatin, carboplatin, doxorubicin, fluorouracil, vincristine, etoposide, irinotecan, gemcitabine, oxaliplatin and sorafenib for children with hepatoblastoma or hepatocellular carcinoma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Sorafenib
    • Etoposide
    • Carboplatin
    Austria Belgium Czechia France Germany Ireland +4

  • Study on Clemizole Hydrochloride for Children and Adults with Dravet Syndrome

    Recruiting

    3 1
    Investigated Diseases:
    • Severe myoclonic epilepsy of infancy
    Investigated Drugs:
    • Clemizole Hydrochloride
    Hungary Poland Spain

  • Study on Sacubitril and Valsartan to Prevent Heart Damage in Breast Cancer Patients Undergoing Treatment

    Recruiting

    3 1 1
    Investigated Diseases:
    • Cardiac failure
    Investigated Drugs:
    • Sacubitril
    • Valsartan
    Poland

  • Study on Doxorubicin, Fluorouracil, and Oxaliplatin for Children and Adolescents with Primary Malignant Liver Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hepatoblastoma
    Investigated Drugs:
    • Sorafenib Tosilate
    • Sodium Thiosulfate
    • Etoposide
    Poland

  • Study on Early Rituximab Treatment for Children with Nephrotic Syndrome

    Recruiting

    3 1 1
    Investigated Diseases:
    • Nephrotic syndrome
    Investigated Drugs:
    • Rituximab
    Poland

  • Study on Valsartan for Slowing Aortic Root Dilatation in Children and Young Adults with Marfan Syndrome and Related Conditions

    Recruiting

    3 1 1
    Investigated Diseases:
    • Arterial tortuosity syndrome
    • Ehlers-Danlos syndrome
    • Loeys-Dietz syndrome
    Investigated Drugs:
    • Valsartan
    Poland

  • Study on the Safety of Ticagrelor and Aspirin in Patients with Acute Coronary Syndrome

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Acute coronary syndrome
    Investigated Drugs:
    • Ticagrelor
    • Acetylsalicylic Acid
    Poland

  • Study on Ivabradine for Preventing Heart Injury in Patients with Atherosclerosis Undergoing Noncardiac Surgery

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Ivabradine
    Poland

  • Study on Cannabidiol as Add-on Therapy for Seizures in Patients Aged 1-65 with Tuberous Sclerosis Complex

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Tuberous sclerosis complex
    Investigated Drugs:
    • Cannabidiol
    Poland

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!